CAR T-cell therapy wins expert panel approval for leukemia treatment: What does this mean for myeloma patients?

On Wednesday, an advisory panel convened by the US Food and Drug Administration (FDA) voted 10 to 0 to recommend the approval of CAR T-cell therapy for treatment of children and young adults with late-stage leukemia. Novartis’s CTL019 is a gene-altering treatment directed against the protein CD19 found on the leukemic B-cells. Wednesday’s unanimous endorsement paves the way for the first gene therapy to win FDA approval, which is expected in September.

Are Cure Claims for CAR T-Cell Therapy Premature?

The top news to come out of the 2017 Annual Meeting of the American Society of Clinical Oncology (ASCO), which concluded on Tuesday, focused on claims that immune cellular therapy with CAR T-cells provides a potentially curative approach for myeloma. It is way too soon, in my opinion, for such suggestions, both in terms of treatment benefit and toxicities and/or side effects.

Measles Virotherapy: Will This Lead to a Cure?

This week I had a chance to talk to Dr. Stephen Russell of the Mayo Clinic about the new measles virotherapy findings and the future of virotherapy for myeloma patients, including a virus that may be an even more potent destroyer of myeloma than the measles virus!

Caring Enough to Find and Sustain a Cure

The United States is running out of Methotrexate®, which is part of a drug cocktail that cures acute lymphatic leukemia in children. Why?